Study assessing benefit of Paxlovid in adults aged ≥18 years in the United States and to assess the association between receiving a prescription for Paxlovid and hospitalization with a COVID-19 diagnosis
Latest Information Update: 07 Dec 2022
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 07 Dec 2022 New trial record
- 02 Dec 2022 Results published in the Morbidity and Mortality Weekly Report